Recent studies focus on identifying molecular targets in chondrosarcomas, revealing intricate genetic aberrations, such as mutations in IDH genes, and dysregulation of signaling pathways like Hedgehog, mTOR, and vascular endothelial growth factor (VEGF) [6,7]. This evidence concerns the gene IDH2 and chondrosarcoma.